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Background: Repetitive Transcranial Magnetic Stimulation (rTMS)/ Deep-brain Magnetic Stimulation (DMS) is an
effective therapy for various neuropsychiatric disorders including major depression disorder. The molecular and
cellular mechanisms underlying the impacts of rTMS/DMS on the brain are not yet fully understood.
Results: Here we studied the effects of deep-brain magnetic stimulation to brain on the molecular and cellular
level. We examined the adult hippocampal neurogenesis and hippocampal synaptic plasticity of rodent under stress
conditions with deep-brain magnetic stimulation treatment. We found that DMS promotes adult hippocampal
neurogenesis significantly and facilitates the development of adult new-born neurons. Remarkably, DMS exerts
anti-depression effects in the learned helplessness mouse model and rescues hippocampal long-term plasticity
impaired by restraint stress in rats. Moreover, DMS alleviates the stress response in a mouse model for Rett syndrome
and prolongs the life span of these animals dramatically.
Conclusions: Deep-brain magnetic stimulation greatly facilitates adult hippocampal neurogenesis and maturation, also
alleviates depression and stress-related responses in animal models.
Keywords: Deep-brain magnetic stimulation, Adult hippocampal neurogenesis, Long-term potentiation, Depression,
MeCP2, Rett syndromeBackground
Transcranial magnetic stimulation (TMS) is a non-
invasive approach of brain stimulation, which utilizes an
insulated coil placed over the scalp and induces neural
activity within the brain [1-3]. TMS is commonly applied
in single, paired or repetitive trains. Repetitive TMS
(rTMS) has been proven to modulate motor skills and
cognitive function in healthy subjects and exhibits thera-
peutic effects for patients with neurological and psychi-
atric disorders [4,5]. Daily prefrontal TMS was approved* Correspondence: zqiu@ion.ac.cn; lxu@vip.163.com
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unless otherwise stated.by Food and Drug Administration (FDA) in 2008 for the
treatment of patients with major depressive disorder.
Recently, deep-brain magnetic stimulation (DMS) with a
modified rTMS protocol has been developed and dem-
onstrated to be effective for Parkinson’s disease and
neuropsychiatric disorders, including depression [6,7].
Despite the indubitable contribution of rTMS/DMS to
cognitive and motor functions of nervous system, the mo-
lecular and cellular mechanisms underlying the anti-
depression effects of rTMS/DMS remain largely unknown.
The prevailing hypothesis is that rTMS may stimulate
neural activity in certain brain regions by modulating the
balance between excitatory and inhibitory neurons [8-12].
Depression is a leading cause of psychiatric disability
worldwide. During the past decade, the adult neurogen-
esis hypothesis of depression has been widely accepted,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Schematic illustration of the new DMS paradigm.
(A) Illustration of Uniform and Linear magnetic fields generated
by this equipment. Composition of Program 1 (A) and Program 5
(B). (C) Body weight changes of mice under control, Program1, and
Program5 treatment daily for 3 weeks. (n = 6 for each condition).
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neurogenesis contributes to the pathophysiology of de-
pression, while the biogenesis of adult new-born neurons
in the dentate gyrus (DG) of hippocampus is required
for the beneficial effects of antidepressant treatment
[13-15]. In non-human primates, stress led to a decrease
in adult hippocampal neurogenesis, which was rescued
by antidepressant treatment [16]. Chronic rTMS treat-
ment exhibited robust anti-depression effects in animal
models and might enhance adult neurogenesis under
chronic stress [17,18].
Here we show that DMS increases the proliferation of
hippocampal neural progenitor cells in the adult brain,
promotes the dendritic complexity of new-born neurons
and enhances the neuronal activity in hippocampus, in-
dicated by the up-regulation of activity-dependent genes.
Moreover, administration of DMS not only alleviates the
depression and anxiety-associated behaviors of a mouse
model for Rett syndrome, but also strikingly prolongs
the lifespan of these animals.
Results and discussion
DMS promotes adult hippocampal neurogenesis
To examine the effects of DMS on adult hippocampal
neurogenesis in wild-type animals, we applied the DMS
protocol to 6 weeks old wild-type mice 20 minutes daily.
The schematic illustration of the DMS device is shown
in (Additional file 1: Figure S1A). Two magnetic stimu-
lating coils are symmetrically placed on the both sides of
the mouse cage. The stimulus device can be discharged
through two coils to produce a time-varying pulsed mag-
netic field. The first stimulating procedure (Program1) is
shown in Figure 1A. In this strategy, the magnetic flux
density is linear gradient. The magnetic pulse is bipolar,
as shown in Additional file 1: Figure S1C,E. The second
stimulating paradigm (Program 5) is shown in Figure 1B.
Different with Program1, the magnetic flux density of
Program 5 is uniform alternating linear gradient, both
magnetic fields are illustrated in Additional file 1: Figure
S1B-E. First, we examined whether DMS stimulation
would have global effects on the general health of ex-
perimental animals. We measured the body weights of
mice receiving either Program 1 (P1) or Program 5 (P5)
treatment daily for 3 weeks and found that P1 or P5
treatment didn’t affect the body weight changes compar-
ing to naïve mice (Figure 1C).
To investigate the role of DMS in the proliferation of
neural stem cells, we applied a short-term bromodeox-
yuridine (BrdU) labeling strategy to monitor postnatal
hippocampal neurogenesis in the mice subjected to
DMS with P1 or P5, respectively. For the thymidine ana-
log incorporation assay, BrdU was administered into
adult mice 4 times with 2-hour interval by intraperi-
toneal injection after 4 or 7 days treatment of DMS(Figure 2A). The treated animals were sacrificed 2 hours
after the last time of BrdU injection. The staining of BrdU
labels the new-born neurons in the hippocampus. The re-
sults showed a dramatic increase in the number of active
proliferating neural progenitor cells in the subgranular
zone of DG after administration of DMS with P1 for 7 days
rather than 4 days (Figure 2B,C). Intriguingly, stimulation
Figure 2 DMS promotes adult hippocampal neurogenesis in rodents. (A) Outline of DMS and BrdU injection experiments. (B) Hippocampal
DG BrdU immunostaining on mice with continuous DMS with Program 1 treatment. Red: BrdU; Blue: DAPI staining. (C) Quantification of (B).
Values represent mean (±) SEM (n = 3 animals for each condition; **: P < 0.005, two-tailed student’s t-test). (D) Hippocampal DG BrdU immuno-
staining on mice with continuous DMS with Program 5 treatment. Red: BrdU; Blue: DAPI staining. (E) Quantification of (D). Values represent mean
(±) SEM (n = 3 animals for each condition; ***: P < 0.0005, two-tailed student’s t-test). Scale bar = 50 μm.
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neurons in the DG as early as 4 days after treatment, sug-
gesting that different DMS paradigms may generate vari-
ous biological effects for adult neurogenesis (Figure 2D,E).
To further confirm whether DMS treatment enhances
proliferation of neural progenitors, we further per-
formed immunostaining using antibody against Ki67, a
cell proliferating marker on these samples. We found
that the number of Ki67- positive cells was significantly
increased in DG area after P5 treatment for 7 days, indicat-
ing that DMS treatment promotes neural progenitor pro-
liferation (Figure 3A,B). To validate that the BrdU-labeled
cells are proliferating progenitors, we performed co-immu-
nostaining for both BrdU and Ki67 and found 100% of
colocalization between the two markers. (Additional file 2:
Figure S2A-D). Furthermore, to reveal the cellular identity
of BrdU-positive cell we performed immunostaining using
antibodies against more neural progenitor markers includ-
ing radial glial-like cell (RGL) marker glial fibrillary acidicprotein (GFAP), immature neuron marker doublecortin
(DCX), and intermediate progenitor (IPC) marker T-box
brain 2 (Tbr2). We found that cells labeled by short-term
BrdU pulse are during actively proliferating process and
show 63% (control) versus 67% (DMS) co-localization with
Tbr2, 21% (control) versus 16% (DMS) with GFAP, and
14% (control) versus 15% (DMS) with DCX (Additional
file 2: Figure S2E-H and Additional file 3: Figure S3A-H).
Taken together, our results indicated that DMS promotes
not only the self- renewal of RGLs but also their differenti-
ation into IPCs and late neuroblasts.
Next, we examined the effect of DMS treatment on
adult hippocampal neurogenesis by in aged animals, in
which the rate of adult neurogenesis remains in a much
lower level than adult mice. The observation that aging
has a negative effect on the proliferation of neural stem
cells [19] has called up efforts to boost neurogenesis
in senescent animals, which will have beneficial effects
for age-related cognitive decline. To study whether DMS
Figure 3 DMS promotes neural progenitors proliferation in rodents. (A) Hippocampal DG Ki67 immunostaining on mice with continuous
DMS with Program 5 treatment for 7 days. Blue: DAPI; Green: Ki67 staining. Right panel: Amplification of boxed area of left panel. Scale bar = 100 μm.
(B) Quantification of (A). (C) Hippocampal DG BrdU immunostaining on 9 month old mice with continuous DMS with Program 1 or 5 treatment.
(D) Quantification of (C). Values represent mean (±) SEM (Animal amounts: Control n = 4, P1 n = 3, P5 n = 4; *: P < 0.05, two-tailed student’s t-test).
Scale bar = 50 μm.
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we applied daily DMS in 9-month old mice for 7 days
and examined the neurogenesis by BrdU incorporation
assay. Our results revealed that the population of prolif-
erating neural progenitors was significantly enhanced
after DMS treatment in P5, while DMS with P1 had a
slight increase but not statistically significant effects on
hippocampal neurogenesis (Figure 3C,D). Thus, we dem-
onstrated that DMS with patterned stimulation proto-
cols promoted the proliferation of hippocampal neural
progenitor cells in both adult and senescent animals.
DMS facilitates the development of new-born neurons
Adult hippocampal neurogenesis largely recapitulates
the process of neural development in embryonic stages.
After birth, new-born neurons in the DG migrate into
the granule cells layer, extend dendrites toward themolecular layer, project axons through the hilus toward
the CA3 and integrate into the existing circuitry [20,21].
To address the effects of DMS on the maturation of
new-born neurons, we labeled these neurons by stereo-
tactic injection of retrovirus into the DG of young mice,
followed by the 2-week daily treatment of DMS with dis-
tinct programs (Figure 4A) [22]. Retroviral infection of
proliferating neural progenitor cells with the introduction
of green fluorescent protein (GFP) allows the sparse label-
ing of new-born neurons and the elaborate observation of
their morphological complexity. The morphology of GFP
labeled new-born neurons was examined with confocal
microscopy at 2 weeks post-injection (Figure 4B). The re-
sults showed that there was a significant increase in both
the number of the tips and total dendritic length after
DMS treatment with either P1 or P5, when compared
to the control GFP labeled neurons (Figure 4C-E). We
Figure 4 DMS facilitates development of DG new-born neurons. (A) Outline of DMS and retroviral-based new-born neuron label experi-
ments. (B) GFP immunostaining with retroviral labeled new-born neurons after DMS treatment for 2 weeks. Green: GFP; Blue: DAPI staining. (C,D)
Total dendritic length and tip numbers measured from (B) Values represent mean (±) SEM (n = 4 animals for each group; **: P < 0.005, ***: P < 0.0005,
two-tailed student’s t-test). (E) Accumulative curve of dendritic length of neurons undergoing control, P1 and P5 treatment. (F) GFP immunostaining
with retroviral labeled new-born neurons after DMS treatment for 4 weeks. Green: GFP; Blue: DAPI staining. (G,H) Total dendritic length and tip
numbers measured from (F) Values represent mean (±) SEM (Animal amounts, control:n = 4, P5:n = 3; **: P < 0.005, *: P < 0.05, two-tailed student’s t-test).
Scale bar = 25 μm.
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mice which received retrovirus injection ahead of sti-
mulation and analyzed the dendritic morphogenesis of
new-born neurons (Figure 4F). Consistently, the results re-
vealed that DMS robustly facilitated the dendritic growth
and branching of neurons (Figure 4G-I).In order to examine whether DMS may affect the de-
velopment of mature neurons, we performed Golgi
staining on the brain sections from control and DMS-
treated animals (Additional file 4: Figure S4A,B). We
measured the spine density of DG granule neurons after
DMS for 2 weeks and found that DMS has no effects on
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Figure S4C,D).
Collectively, these evidences demonstrated that DMS
treatment not only enhances the proliferation of adult
neural progenitor cells in DG, but also facilitates the de-
velopment and maturation of new-born neurons, sug-
gesting that new-born neurons induced by DMS are able
to incorporate into hippocampal neural circuitry and
contribute to neuronal plasticity of the central nervous
system.
DMS stimulates gene expression in hippocampus in vivo
To further explore the consequences at the molecular
level caused by DMS treatment, we performed im-
munostaining and quantitative PCR to examine the
change of gene expression in the hippocampus in vivo.
Neural activity induces the modification of synaptic
proteins, promotes local protein synthesis within den-
drites and activates gene transcription in neurons.
Therefore, we compared the expression level of several
activity-dependent genes in the hippocampus between
control groups and DMS-treated groups. The immediateFigure 5 DMS stimulates gene expression in hippocampus. (A) Immun
DMS with P5 treatment for 4 days. (B) Quantitation for c-fos positive cells in
*: P < 0.05, student’s t-test). (C) mRNA level of fgf1b gene in hippocampus a
each conditions; *: P < 0.05, student’s t-test). (D) Protein level of Fgf1b afte
collected from control and animals received P5 daily treatment for 4 days
antibodies indicated. (E) Quantification of (D).early genes including c-fos, egr1 and arc are commonly
used as markers for measuring neuronal activity in the
brain. We first examined the expression of immediate
early gene c-fos, in the DG after daily DMS with P5 para-
digm for 4 days by immunohistochemistry. The results of
immunostaining showed that the population of c-fos-
positive neurons was significantly increased in DMS-
treated animals (Figure 5A,B). Additionally, the Fgf1b gene
is a brain-specific expressing gene encoding an important
neurogenic niche factor in the adult hippocampus, and is
induced by electroconvulsive stimulation [23]. We col-
lected the hippocampal samples from animals with or
without DMS treatment, further examined the mRNA
levels of fgf1b in the DG by quantitative PCR. We found
that the expression level of fgf1b was remarkably elevated
after DMS (Figure 5C). Furthermore, we examined the
protein level of Fgf1 in hippocampus with DMS treatment
for 4 days. Consistently, we found that DMS treatment for
4 days significantly lead to an increase of protein level of
Fgf1 in hippocampus (Figure 5D,E). These results suggest
that DMS stimulation increases neural activity in the
hippocampus, induces the expression of activity-dependentohistochemistry for c-fos expression in hippocampal DG region after
per 1 mm3. Values represent mean (±) SEM (n = 4 for each conditions;
fter DMS with P5 for 4 days. Values represent mean (±) SEM (n = 4 for
r DMS P5 treatment for 4 days. Hippocampal tissue samples were
. Samples were homogenized and analyzed by SDS-PAGE using
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which thereby promotes neurogenesis and plasticity in the
adult brain.
DMS exerts anti-depression effects on rodent model
It is postulated that the defects in adult hippocampus
neurogenesis is strongly associated with major depres-
sive disorder. Exercise may alleviate depression symp-
toms via enhancing neurogenesis in animals [24]. The
rTMS has been an effective therapeutic tool for the
treatment of several neuropsychiatric disorders in hu-
man patients, as well as rats with chronic unpredicted
mild stress (CUMS) [25]. The evidence that application
of DMS to wild type animals increases adult neurogen-
esis prompted us to investigate whether the newly-
developed DMS protocol has anti-depressive effects in
the rodent model. We applied learned helpless animal
paradigm to model some aspects of depression in ro-
dents [26]. Following 2 days of unpredicted electric foot-
shocks, we successfully induce the depression phenotype
in mice assessed by forced swimming test, in which mice
with foot-shocks appeared to have increased immobility
time compared to naïve animals (Figure 6A,B, Additional
file 5: Figure S5A-E). After treating mice with continuous
5-day DMS treatment with P5, we found that the im-
mobility time of depressed mice induced by foot-shock
was fully rescued to normal level by the DMS treatment
(Figure 6B).
The pathophysiology of major depressive disorder has
been characterized by alternations of molecular markers.
Whole-genome expression profiling revealed that mitogen-
activated protein kinase phosphatase-1 (MKP-1) was dys-
regulated in the hippocampal tissues from patients with
depression, suggesting that MKP-1 serves as a molecular
marker for depression [27]. Consistently, the expression
level of MKP-1 was significantly up-regulated in the hip-
pocampus of mouse model with depression phenotypes
(Figure 6C). Importantly, the dys-regulated expression of
MKP-1 in depressed mice was completely restored by the
DMS treatment (Figure 6C).
Next we investigated whether increased adult hippo-
campal neurogenesis induced by DMS plays a critical
role in alleviation of depressive behavior by elimination
of neurogenesis using gamma irradiation (IR). After
applying IR after foot shock, we found that IR abol-
ished the effect of DMS on alleviation of depressive be-
haviors (Figure 6D,E). Meantime, we found that IR
itself also leads to a dramatic decrease of hippocampal
adult neurogenesis (Additional file 6: Figure S6A-C).
Furthermore, mood disorder induced by acute stress
impairs long-term potentiation (LTP) in the neural cir-
cuitry of hippocampus [28-31]. The effects on synaptic
plasticity occur following a plethora of stressors includ-
ing administration of shock, exposure to a predator or anovel environment [32]. We used chronic restraint stress
paradigm to induce depression in rats and recorded LTP
in hippocampus by in vivo electrophysiological recording.
Indeed, LTP was found to be impaired in rats undergoing
restraint stress (Figure 6F). Notably, DMS treatment for
7 days largely rescued the deficit LTP induction in de-
pressed rats (Figure 6F,G). These behavioral, molecular
and electrophysiological evidences strongly support that
short-term DMS treatment is effective for alleviating
depression-associated phenotypes in animal models.
DMS alleviates anxiety-associated phenotypes in a mouse
model for Rett syndrome
Finally we would like to further examine whether DMS
could alleviate the anxiety-related behaviors in other dis-
ease models. Rett syndrome is a severe neural develop-
mental disorder, primarily caused by loss-of-function
mutations of gene MECP2 (Methyl-CpG-binding protein
2) [33-35]. The mouse carrying a truncated form of
MeCP2 protein (mecp2308/y) mimics severe phenotypes
of Rett syndrome patients, including elevated anxiety
and stress responses [36]. Thus we asked whether DMS
could help to relieve the anxiety-associated phenotypes
in mice carrying mecp2308/y mutation.
We first examine stress responses in mecp2308/y mouse
and its wild type littermates, using light–dark transition
paradigm. We found that mice carrying mecp2308/y mu-
tant appeared to spend much less time in light compart-
ment and thus to have increased anxiety levels
(Figure 7A,B). Interestingly, chronic daily DMS treat-
ment for 5 months restored elevated anxiety levels of
mecp2308/y mice to normal level (Figure 7A,B). Thus,
DMS treatment appears to have significant effects to
regulate the anxiety levels of animals for disease models.
Lastly, we asked whether DMS treatment would make
positive impacts to the general health of the mouse
model of Rett syndrome. Lack of MeCP2 in mouse
would lead to significant shortage of lifespan [37,38].
We acquired nervous system specific mecp2 knockout
mice by crossing mice carrying neuronal specific Cre
transgene nestin-cre with mecp2 floxed allele- mecp2flox/y.
We found that loss of MeCP2 in the nervous system
would lead to substantial shortage of lifespan down to
around 130 days or so (Figure 7C). Surprisingly, mice
with nestin-cre, mecp2flox/y received daily DMS with
either P1 or P5 appeared to have enormously extended
lifespan (Figure 7C), indicating that long-term treat-
ment of DMS indeed exerts positive effects on the gen-
eral health to mouse model of Rett syndrome.
Discussion
The growing interest in noninvasive brain stimulation
generated by TMS led to its widespread application to
treat various neurological and psychiatric disorders
Figure 6 DMS rescues stress-induced phenotypes and synaptic plasticity in rodent models. (A) Outline of foot-shock-induced depressive
behavioral paradigm and DMS treatment experiments. (B) Behavioral effects of learned helplessness mouse model with DMS treatment. Values
represent mean (±) SEM (Animal amount: control n = 15, Foot-shock n = 19, Foot-shock with DMS n = 15; **: P < 0.005, two-tailed student’s t-test.
(C) Hippocampal Mkp-1 mRNA level in a learned helplessness mouse model with DMS treatment. Values represent mean (±) SEM (n = 12 animals
for each group; *: P < 0.05, two-tailed student’s t-test). (D) Outline of foot-shock-induced depressive behavioral paradigm, DMS treatment, and gamma
irradiation experiments. (E) Behavioral effects of learned helplessness mouse model with DMS and IR treatment. Values represent mean (±) SEM (n = 12-16
for each condition; **: P < 0.005, *: P < 0.05, two-tailed student’s t-test). (F) DMS treatment restored hippocampal LTP impaired by the chronic restraint
stress. Compared with control group (n = 5, 119.92 ± 2.78% of baseline ), the LTP induction was significantly impaired in Restraint Stress (RS) group (n = 5,
97.10 ± 1.67% of baseline) and restored in RS +DMS group (n = 12, 117.06 ± 3.54% of baseline); (G) Summary of LTP induction in control, RS and RS +DMS
group (F(2,19) = 8.64, *p = 0.002, compared with control group). Statistical comparisons in electrophysiological studies were made by the least significance
difference test of one-way ANOVA. The significance level was set as *:p < 0.05.
Zhang et al. Molecular Brain 2014, 7:11 Page 8 of 14
http://www.molecularbrain.com/content/7/1/11including major depression and Parkinson’s disease.
The NeuroStar TMS Therapy system (Neuronetics,
Inc., Malvern, PA, USA) received FDA clearance for the
treatment of adult patients with intractable depression
in 2008. It is assumed that magnetic stimulation makesuse of electromagnetic principles to alter neural activity
non-invasively, and induces focal as well as network
effects in the brain. However, how rTMS changes the
cellular behavior and functional connectivity remains
enigmatic.
Figure 7 DMS alleviates anxiety-associated defects and extend life span in mouse model for Rett syndrome.
(A) Time spent in light compartment during light–dark transition tests. Values represent mean (±) SEM (Animal amounts, wt n = 8, mecp2308/y n = 9,
mecp2308/y + DMS n = 9; **: P < 0.005, *: P < 0.05, two-tailed student’s t-test). (B) Times of light–dark transitions during test. Values represent mean (±)
SEM (*: P < 0.05, two-tailed student’s t-test). (C) Kaplan-Meier survive curve of nestin-cre, mecp2flox/y mice with control, DMS with P1 and P5 treatments,
respectively. (n = 4 for each condition).
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as DMS, to help the learned helpless animals recuperate
from stress and depression. The short-term application
of DMS to depressed mice not only improved their
stress-related behavior but also amazingly reversed the
pathophysiology of major depression, indicated by the
alteration of molecular marker and neuronal plasticity.
As the neurogenic hypothesis of depression gains momen-
tum over the last decade, more and more evidence con-
firmed that the waning and waxing of neurogenesis in the
hippocampus are important causal factors in the precipita-
tion of and recovery from depression, respectively. Our
study provided several lines of evidences to prove that
DMS treatment increases adult neurogenesis and new-
born neuron maturation in vivo. First, short-term DMS
administration rapidly induces the proliferation of adultneural progenitors in the subgranular zone of DG. The
enhanced neurogenesis by DMS treatment occurs in
both adult and senescent animals. Second, the applica-
tion of DMS to adult animals promotes the dendritic
development new-born granule neurons, suggesting the
elevated incorporation of new-born neurons into exist-
ing hippocampal circuitry might be achieved by mag-
netic stimulation. Finally, DMS treatment is shown to
up-regulate the neural activity, which is beneficial to in-
crease the production and release of neurogenic niche
factors such as FGF1b. Thus, our results support the
notion that DMS is an efficient therapeutic treatment
for major depression disorders and the antidepressant
effects of DMS may rely on the elevation of hippocam-
pal adult neurogenesis and the modulation of hippo-
campal synaptic plasticity.
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this local niche, regulate multiple stages of adult neuro-
genesis, from neural progenitor proliferation to newborn
neuron maturation, synaptic integration and survival.
Our study shows a new non-invasive way to enhance
adult hippocampal neurogenesis probably by changing
the network activity of hippocampus and inducing a
beneficial neurogenic niche in the subgranular zone. Re-
petitive electrical stimulation in adult hippocampal slices
induces NMDA receptor-dependent LTP and high fre-
quency stimulation results in persistent increase in syn-
aptic strength [39]. Studies using theta-burst stimulation
protocols provide solid evidence linking human rTMS
with LTP-like plasticity [40,41]. The DMS protocol we
applied exerts high frequency oscillated stimulation in
the brain of animal models and rescues the deficient
LTP impaired by restraint stress in rats. On the other
hand, LTP induction in the anesthetized rats increases
neurogenesis in the dentate gyrus and FGFR activation
by the neural cell adhesion molecule promotes neural
progenitor proliferation by enhancing LTP [42,43].
Therefore, the study suggests that DMS administration
may promote adult neurogenesis by inducing high fre-
quency theta-burst stimulation and LTP in the hippo-
campus. Further study will be performed to explore the
alteration of field potential by DMS treatment. More-
over, the finding that DMS alleviates stress response and
prolongs the life expectancy of mouse model for Rett
syndrome is particularly intriguing. Many trials have
been carried out to examine whether drug delivery or
genetic manipulation help to alleviate the impaired be-
havior and severe pathophysiology of Rett syndrome
mouse model [44-46]. Although gene delivery of Mecp2
seems to completely rescue various symptoms in animal
models of disease, the efficacy and safety issues of gene
delivery remain controversial. Here our results suggest a
modified DMS paradigm which may relieve the stress-
related symptoms, as well as improve the life quality of
Rett syndrome patients. Further study of how DMS
treatment may contribute the neural plasticity of the
central nervous system under disorder conditions are
very critical for deepen our understanding of therapeutic
efforts towards the cure of neurodevelopmental disor-
ders and neuropsychiatric disorders. In order to develop
easier and more effective therapy for patients with neu-
rodevelopmental disorders and neuropsychiatric disor-
ders, we need to better understand how DMS treatment
contributes to the neural plasticity of central nervous
system under pathological conditions.
Conclusion
Taken together, we report that a new DMS paradigm rap-
idly induces adult hippocampal neurogenesis and pro-
motes development of DG new-born neurons. Our studyprovides a new non-invasive way to enhance adult hippo-
campal neurogenesis within a short period of time and
make it possible to study the role of adult hippocampal
neurogenesis in a gain-of-function manner. More import-
antly, we provided evidences that this new DMS paradigm
efficiently rescues behavioral phenotypes and gene expres-
sion profiles in learned helplessness mouse model, as well
as restoring hippocampal LTP impaired by restraint stress
in rats. These results support the notion that DMS is an
efficient therapeutic treatment for major depression disor-
ders and strongly suggest that the antidepressant effect of
DMS on depression disorders may rely on the improve-
ment of hippocampal adult neurogenesis and the correc-
tion of hippocampal synaptic plasticity.
Methods
Animals
Animals were group-housed with free access to water
and food in the established animal houses, with a
12 hours light/dark cycle and a thermo-regulated envir-
onment. The use and care of animals complied with the
guideline of the Biomedical Research Ethics Committee
at the Shanghai Institutes for Biological Science, CAS.
Adult (6–7 weeks old) male C57BL/6 mice (SLAC Labora-
tory Animal) were used in all experiments except electro-
physiology trials which were performed on male Sprague
Dawley rats (Animal House center, Kunming General
Hospital, Kunming), weighing 220–250 g. mecp2308/y mice
(005439) and nestin-cre mice (003771) were purchased
from Jackson lab; floxed mecp2 (011918) were purchased
from MMRRC at UC Davis.
DMS treatment
For DMS treatment, mice with their cage were placed in
DMS machine. Metal parts of cages were removed prior
to DMS treatment. The applied program was described in
Supplementary Figures. Briefly, twenty minutes successive
trains of DMS were administered daily for different
consecutive days depending on the purpose of experi-
ments.14 days DMS were administered on retrovirus
injected mice and 4 or 7 days DMS on Brdu labeled mice
while 5 days DMS on acute induced depression mice. The
control group conditions were identical to their DMS
group but received sham stimulation. For electrophysi-
ology experiments, control group received no treatment,
Restraint stress (RS) group were restrained in the fixing
cage 20 min each day for 7 days, RS + DMS group re-
ceived 20 min DMS treatment in the fixing cage for 7 days.
Electrophysiology studies were carried out 0.5 h later after
the last restraint stress or DMS treatment.
In vivo electrophysiology
Experiments were carried out on rats anesthetized with
pentobarbital (60 mg/kg, i.p.), and core temperature was
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postsynaptic potentials (EPSPs) were made from the
CA1 stratum radiatum of the hippocampus in response
to ipsilateral stimulation of the Schaffer collateral/com-
missural pathway using techniques described previously
[28,47]. Recording and stimulating electrodes were made
by gluing together a pair of twisted Teflon-coated 90%
platinum and 10% iridium wires (50 μm inner diameter,
75 μm outer diameter; World Precision Instruments,
Sarasota, FL). The recording electrode was inserted
3.8 mm posterior to bregma and 2.8 mm right of the
midline, and the stimulating electrode was inserted
4.8 mm posterior to bregma and 3.8 mm right of the
midline. The optimal depth of the wire electrodes in the
stratum radiatum of the CA1 area of the dorsal hippo-
campus was determined by electrophysiological criteria.
Test EPSPs were evoked at a frequency of 0.033 Hz and
at a stimulus intensity adjusted to give an EPSP amplitude
50% maximum response. The high frequency stimulation
(HFS) protocol for inducing LTP consisted of 10 stimulus
trains of 20 pulses at 200 Hz, with 2 s intertrain intervals.
EPSP amplitude was expressed as mean ± S.E.M% of the
baseline EPSP amplitude recorded over a 40-min baseline
period, and amplitudes in the last 10-min of recording
were averaged in one animal and then across animals to
give a value for the group.
Preparation and stereotaxic injection of retrovirus
We thank Drs. Hongjun Song (Johns Hopkins University
School of Medicine) and Zhengang Yang (Institutes of
Brain Science, Fudan University) for providing retroviral
constructs and supernatant containing retrovirus. Cell
debris were removed from supernatant through 0.22 μm
filter and the filtered supernatant was centrifuged at
65000 g at 4°Cfor 2 h. Then supernatant was removed and
50 μl PBS was used to re-suspend virus. We seed 293 T to
determine the titer of virus. High titer virus of 108vg/ml
was necessary to label new-born neurons in the adult DG.
For stereotaxic injection, it is critical to locate the
exact hippocampus neurogenic area. The mouse was
mounted onto the stereotaxic frame, orienting the head
straight in terms of anterior-posterior axis and horizon-
tally. Then we shaved a small area by a trimmer, cut the
skin over the scull, cleaned up the blood in the wound.
The needle was firstly moved to the bregma and then
moved posteriorly 2.0 mm and laterally 1.5 mm to the
injection position. A small hole was made on the scull
using an electric drill and the needle tip was moved
down by 2.25 mm from the water level of the hole. 1 μl
retrovirus solution was injected to one side.
For both Brdu and retrovirus stereotaxic injection sta-
tistics, each group (control, program1 and program5)
has 4–5 mice. Each mouse was collected 9–12 slices
from dorsal to ventral region of DG. And 1 or 2 intactneurons were chosen from each slice for analysis. ImageJ
software (http://rsbweb.nih.gov/ij/) was used to trace the
dendrites of new-born neuron. Then the dendritic length
and tips number were auto-analyzed.
Bromodeoxyuridine injection
Mice received four or seven days DMS treatment and
Bronodeoxyuridine (Brdu) (50 mg/kg in saline, every
two hours for four times, Sigma, flu/Ald, B5002) was in-
traperitoneally (i.p.) injected into the control or DMS
group mice 12 hours after the last DMS treatment. Mice
were killed two hours later after the last i.p. injection.
Tissue preparation, immunostaining and imaging
Mice were transcardially perfused with 0.1 M cold PBS
followed by 4% paraformaldehyde (PFA) fixation. The
brains were post-fixed for 12 hours in 4% PFA and dehy-
drated in 30% sugar solution for another 12 hours. Cor-
onal sections of 40-μm thickness were cut on the freezing
microtome (LEICA CM1950) and stored in PBS.
For Brdu immunostaining, free-floating sections were
incubated in 2 N HCl for 15 min at 37 degree then neu-
tralized in 0.1 M boric acid solution (pH 8.5) for 10 min
and washed by PBS for 3 times (each time for 5 minutes).
Sections were incubated in mouse anti-Brdu antibody
(1:1500; MAB3510) at 4 degree overnight and washed
again then incubated in CF555 conjugated donkey anti-
mouse secondary antibody (1:500; Biotum,20037) for
2.5 hours at room temperature.
For GFP immunostaining, free-floating sections were in-
cubated in mouse anti-GFP antibody (1:1000;Santa Cruz,
9996) at 4 degree overnight and washed again then incu-
bated in CF488 conjugated goat anti-mouse secondary
antibody (1:500;Biotum,20010) for 2.5 hours (dark) at room
temperature.
Immunostaining sections were photographed in Z-series
stacks using a Nikon A1 confocal microscope. NIH Image J
with NeuronJ plugin was used to count the Brdu-im-
munoreactive cell number in the dentate gyrus and to
quantify the area of the dentate gyrus, also to analyze total
dendritic length of GFP+ new-born neurons.
Statistical analysis
The results were expressed as Mean ± S.E.M. Statistical
significance (P < 0.05) was assessed using the two-tailed
Student’s t-test.
Learned helplessness paradigm
Mice were placed into the inescapable shock chamber.
360 scrambled foot shocks (0.6 mA) with varying dur-
ation (1-3s) and interval-episodes (1-15s) were delivered
over two consecutive days. Control group did not re-
ceive foot shocks but were placed to the shock chamber
with equal time. On the first and second days, 8 hours
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mice were administered DMS for another 3 days.
Forced swim test
Mice were placed individually in the testing cylinder
(33 cm high × 10 cm in diameter) containing water with
20 cm depth. The procedures were conducted as two
minutes pretest followed by four minutes test and both
sessions were videotaped. Observers scored the immo-
bility (floating passively with slight movements) time in
the test four minutes.
Gamma irradiation
Mice were anesthetized with 0.7% Pentobarbital sodium
at 10ul/g, and exposed to cranial irradiation at a field of
3.5×11mm above the hippocampus but other body parts
were protected with a 75 mm lead shield. Caesium-137
was used as radioactive source operated by MDS Nor-
dion GC-3000Elan. The dose rate was approximately
4 Gy per min. The procedure lasted 5 min and 30 sec,
delivering a total of 20 Gy in the center.
Light–dark transition
mecp2308/y mutant mice were carried out light–dark
transition test after daily DMS stimulation for 5 month
at the age of 5–6 month. The chamber is divided into
two unequal compartments by an opaque shelter with a
hole (of height 4 cm) at the floor level. The smaller com-
partment (18cm×27cm×30cm) is painted black and cov-
ered by an opaque lid while the larger compartment
(27cm×27cm×30cm) is uncovered and is illuminated by
ceiling room lights. Firstly, mice were gently placed into
the dark compartment. Transition between the two
compartments and time spent in the light compartment
were automatically recorded by the Ethovision video-
tracking system in a 10 min session.
Quantitative real time PCR
Total RNA was collected from fresh hippocampus tissue
for reverse transcription (Bio-Rad, 1708891). 2 × SYBR
Green Master Mix (TOYOBO, QPK201) and QIAGEN
Rotor-Gene Q machine were used in real time PCR ex-
periments. Mouse MKP-1 real time primer: forward:
CGCTTCTCGGAAGGATATGCT; reverse: GTCAATA
GCCTCGTTGAACCAG. Fgf1b primers were used as
reported [23].Additional files
Additional file 1: Figure S1. Illustration of DMS equipment and
magnetic fields. (A) The positions of animal and DMS machine are
showed. (B-C) Illustration of magnetic vector potential generated during
Uniform and Linear phase by DMS equipment. (D-E) Illustration of
Uniform and Linear magnetic fields generated by this equipment.Additional file 2: Figure S2. The effect of DMS to adult hippocampal
neurogenesis. A) Hippocampal DG Ki67 and BrdU immunostaining on
mice with continuous DMS with P5 treatment for 7 days. Blue: DAPI;
Green: Ki67; Red BrdU staining. (B) Quantification of (A). (C) Hippocampal
DG Ki67 immunostaining on mice with continuous DMS with P5
treatment for 7 days. Blue: DAPI; Green: Ki67 staining. Lower right panel:
Amplification of boxed area of (A) panel. (E) Hippocampal DG GFAP and
BrdU immunostaining on mice with continuous DMS with P5 treatment
for 7 days. Blue: DAPI; Green: GFAP; Red BrdU staining. (F) Quantification
of (E). (G) Hippocampal DG GFAP immunostaining on mice with
continuous DMS with P5 treatment for 7 days. Blue: DAPI; Green: GFAP
staining. Lower right panel: Amplification of boxed area of (G) panel.
Scale bar = 100 μm.
Additional file 3: Figure S3. The effect of DMS to adult hippocampal
neurogenesis (Continued). (A) Hippocampal DG Tbr2 and BrdU
immunostaining on mice with continuous DMS with P5 treatment for
7 days. Blue: DAPI; Green: Tbr2; Red BrdU staining. (B) Quantification of
(A). (C) Hippocampal DG Tbr2 immunostaining on mice with continuous
DMS with P5 treatment for 7 days. Blue: DAPI; Green: Ki67 staining. Lower
right panel: Amplification of boxed area of (C) panel. (E) Hippocampal DG
DCX and BrdU immunostaining on mice with continuous DMS with P5
treatment for 7 days. Blue: DAPI; Green: DCX; Red BrdU staining. (F)
Quantification of (E). (G) Hippocampal DG DCX immunostaining on mice
with continuous DMS with P5 treatment for 7 days. Blue: DAPI; Green:
DCX staining. Lower right panel: Amplification of boxed area of (G) panel.
Scale bar = 100 μm.
Additional file 4: Figure S4. The effect of DMS to development of
mature hippocampal DG neurons. Example pictures of Golgi staining for
hippocampal DG neuron in control (A) and DMS (B) condition. (C) Golgi
staining for spines on hippocampal DG neurons. (D) Quantification of (C).
(E) Immunohistochemistry for c-fos protein in laternal habenula region
after DMS with P5 treatment for 4 days. (F) Quantification of (E).
Additional file 5: Figure S5. The effect of DMS on stress-induced
depressive phenotypes in rodent models. (A) Outline of foot-shock-induced
depressive behavioral paradigm and DMS treatment experiments. (B-E)
Behavioral effects of learned helplessness mouse model with DMS treatment
during various time points. Values represent mean (±) SEM (Animal amount:
control n = 15, Footshock n = 19, Footshock with DMS n = 15; **: P < 0.005,
two-tailed student’s t-test.
Additional file 6: Figure S6. IR inhibits adult hippocampal neurogenesis
in rodents. (A) Outline of gamma irradiation (IR) and BrdU injection
experimentsHippocampal DG BrdU immunostaining on control mice (B),
and with IR treatment (C). Red: BrdU; Blue: DAPI staining. (D) Quantification
of (C,D). Values represent mean (±) SEM (n = 12-16 for each condition;
*: P < 0.05, two-tailed student’s t-test). Scale bar = 100 μm.Competing interests
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